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ABSTRACT 
BACKGROUND:  Bordetella pertussis, otherwise known as whooping cough, is a highly 
contagious respiratory disease that was once a significant source of childhood morbidity 
and mortality. The availability and distribution of the pertussis vaccine beginning in the 
1940s and onwards has helped to decrease transmission of infection, resulting in a major 
decline in pertussis incidence among highly immunized countries over time. However, 
there has been a reemergence of pertussis within highly immunized communities, with 
rates progressively increasing over the last 30 years and an observed epidemiological shift 
of higher incidence among adolescent and adult populations. Negative health outcomes in 
pertussis infected children less than one year of age continue to remain a major public 
health concern as intensity of symptoms and delay of recovery in this population often 
leads to hospitalization and even death. 
OBJECTIVES: This systematic review examines published literature in the last ten years to 
provide an up-to-date analysis of the risk factors associated with the resurgence of 
pertussis among highly immunized populations. 
METHODS:  A literature search was conducted using PUBMED and EBSCO databases using 
combination searches with the key words pertussis, whooping cough, resurgence, 
reemergence, recurrence, and comeback. Retrieved articles were refined based on the date 
of publication and on the country in which the study was conducted. Only primary studies 
with data collected between 2004-2014 from highly immunized countries with equal to or 
greater than 90% of three doses of infant pertussis immunization coverage were included 
in this review.  
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RESULTS: Three main groups of risk factors contributing to pertussis reemergence were 
identified among fourteen primary studies. The first category included four studies 
assessing the risk factor of waning immunity. The second category comprised of six studies 
focused on the risk factor of bacterial mutations. A third grouping of articles based on 
immunization status and diagnosis recognition included one article associated with each of 
the following risk factors: non-medical exemptions, inadequate childhood immunizations, 
household transmission, and inadequate provider awareness.  
CONCLUSION: Pertussis resurgence is a complex public health issue involving various 
components and interrelated risk factors. Research into the associated waning immunity 
through use of acellular vaccines and increased understanding of bacterial mutations 
contributing to vaccine ineffectiveness will be important to improving current available 
vaccines and should be a focus of continued efforts through collaboration among multiple 
disciplines. Emphasis on the importance of up to date immunizations among the general 
population and educational interventions directed toward health care providers and 
patients will be key to reducing pertussis transmission in highly immunized countries until 
new vaccines become available.  
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BACKGROUND 
1.1 Introduction 
 One of the top ten public health accomplishments in the twentieth century includes 
the development of vaccines protecting populations against dangerous infectious diseases 
(Centers for Disease Control and Prevention [CDC], 2013). The availability and 
administration of vaccines has helped to control the transmission and incidence of specific 
infectious diseases, which had once been significant sources of morbidity and mortality in 
communities of all ages. Areas of high vaccination coverage, in which large percentages of 
individuals were immunized, allowed for herd immunity to occur.  Herd immunity is the 
concept that unimmunized individuals within a population with high immunization rates 
would be less likely to come into contact with individuals with the disease, thus decreasing 
transmission rates.  However, recently, there has been a recurrence of vaccine preventable 
illnesses in areas where disease was once controlled due to high immunization coverage.  
The reemergence of diseases, once well-controlled among highly immunized communities, 
is becoming a significant public health issue.  One example of this is the recurrence of 
Bordetalla pertussis, otherwise known as whooping cough.  Pertussis is a highly contagious 
respiratory infectious disease that has made a comeback and is negatively affecting the 
health of infants, children, and adults in highly immunized communities (Cherry, J.D., 2012; 
Chiappini, E., Stival, A., Galli, L., Martino, M., 2013). The purpose of this systematic review is 
to examine recent literature published in the last ten years regarding risk factors 
associated with pertussis resurgence among highly immunized populations. 
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1.2 Pertussis Pathophysiology/ Symptoms 
 Pertussis is a respiratory disease caused by the gram–negative bacteria Bordetella 
pertussis in which humans are the only reservoir (World Health Organization [WHO], 
2014). Transmission occurs through the spread of respiratory droplets among individuals 
(Dworkin, M.S., 2005). When a person breathes in the pertussis bacteria, the method of 
infection involves attachment of the bacteria to the cilia in the upper respiratory tract 
causing inflammation and swelling (CDC, 2013). Symptoms of pertussis can start off like 
the common cold but can progress into more serious coughing fits that last anywhere from 
2-10 weeks.  Pertussis progression may also lead to death in some individuals, often due to 
decreased oxygen due to prolonged and frequent coughing. 
 The clinical course of pertussis disease is divided into three stages: catarrhal, 
paroxysmal, and convalescent stages. During the catarrhal stage, possible symptoms 
include mild intermittent cough and low-grade fever. This stage can last anywhere from 4-
21 days though 7-10 days is the average period. Individuals and health care providers may 
associate these symptoms with the common cold during this time, leaving many patients 
misdiagnosed (Dworkin, M.S., 2005). As the cough becomes more severe, the paroxysmal 
stage occurs and is defined by the paroxysmal type coughs. These coughs occur 
simultaneously and rapidly in efforts for the body to rid the lungs of thick mucous which 
has developed.  Another symptom in this stage is the “whoop” sounds, which may occur at 
the end of each paroxysmal cough. Paroxysmal attacks occur at an average of 15 attacks per 
24 hours, often causing vomiting and extreme fatigue.  The usual time period for the 
paroxysmal stage is 1-6 weeks but may last anywhere up to 10 weeks. (CDC, 2013) 
 12
 The last stage of pertussis disease is the convalescent stage and is characterized by a 
recovery time period with decreased frequency of paroxysmal coughs. The usual time 
period for this stage is 7-10 days, with a range of 4-21 days (CDC, 2013). 
 
1.3 Complications of Disease 
 Infants below the age of one year old are at highest risk for developing the 
complications of pertussis. Approximately 50% of infants diagnosed with pertussis are 
hospitalized (CDC, 2013). Additional statistics from the CDC state that among infants who 
are hospitalized:  
● 1 in 4 (23%) get pneumonia (lung infection) 
● 1 or 2 in 100 (1.6%) will have convulsions (violent, uncontrolled shaking) 
● Two-thirds (67%) will have apnea (slowed or stopped breathing) 
● 1 in 300 (0.4%) will have encephalopathy (disease of the brain) 
● 1 or 2 in 100 (1.6%) will die 
Though milder symptoms are often seen in adolescents and adults who contract pertussis, 
complications from the cough can cause weight loss (33%), loss of bladder control (28%), 
passing out (6%), and rib fractures from severe coughing (4%). Less than 5% of teens and 
adults with pertussis are hospitalized (2013).  
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1.4 Diagnosis of Pertussis  
 Pertussis can be diagnosed through several laboratory tests including culture, 
polymerase chain reaction (PCR), and serology.  The CDC (2013) defines culture as the gold 
standard to diagnosing pertussis due to its high specificity and its ability to identify specific 
strains and antimicrobial resistance. As a result, it is the preferred diagnosis method during 
outbreaks. Culture is obtained through nasopharyngeal aspirates or swabs.  
 Polymerase chain reaction (PCR) is another lab test used for pertussis diagnosis in 
patients, though it is often difficult to obtain from infants (Sintchenko, 2008).  PCR tests 
allow for rapid results; however the high sensitivity of the assay may also produce more 
false-positive test results (CDC, 2013). Guiso (2014) addresses this topic of high sensitivity 
versus high specificity of lab tests in the adolescent and adult population arguing that the 
higher false-positive rates with PCR may lead to misdiagnosis, though providing the benefit 
of attaining quicker results for this age group (p. S121). 
 Serological blood test is another diagnostic test available and often beneficial in 
examining pertussis.  Sintchencko (2008) states, “the greatest specificity for the serological 
diagnosis of B. pertussis infection is achieved by the measurement of IgG and IgA 
antibodies against pertussis toxin”(p.143). According to Bamberger, E.S. & Srugo, I. (2008), 
this test is often ineffective for infants with limited “measurable antibodies” though useful 
in older adults who have negative PCR and culture results after a prolonged course of 
whooping cough (p.  136). 
 The varying methods of diagnosis at different stages of symptom presentation can 
make acquisition of consistent measures of disease occurrence difficult.  Guiso (2014) 
discusses the importance of formulating a standardized method for biological diagnosis of 
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pertussis in order to gain a more accurate perspective of pertussis incidence and 
prevalence rates. This is especially important in addressing the actual burden of disease 
occurring in immunized populations and in determining future expectation of outbreak 
occurrence. 
 
 
1.5 Treatment 
 
  Different types of antibiotics for treatment of pertussis are available and are most 
effective if initiated earlier during the course of infection. Schaffner (2006) describes the 
challenges of how delayed diagnosis of pertussis may lead to suboptimal disease outcome, 
where antibiotic use may help symptoms yet do not “alter the course of the disease” (p. 29).  
This is because the exposure to the bacteria has already caused damage to the lining of the 
respiratory tract, and “treatment after three weeks of illness is unlikely to help because the 
bacteria are gone from your body though symptoms are still there” (CDC, 2013). However, 
the identification of infected persons would allow prophylactic treatment to be distributed 
to those who are in close contact with the infected individuals, thus helping to decrease the 
spread of the disease and severity of symptoms in those diagnosed in early stages of the 
disease (Schaffner, 2006). According to Bamberger & Scrugo (2008), the prophylactic 
recommendations in the Academy of Pediatrics Red Book instruct “Chemoprophylaxis to be 
administered to all household contacts and other close contacts, regardless of age and 
immunization status” (p. 136). 
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1.6 Whole Cell Pertussis Vaccine (wP) 
 Until the pertussis vaccine was introduced and dispersed among populations 
through public health efforts, pertussis was one of the main causes of childhood mortality 
in developed countries (Boven, M., Ferfuson, N.M. &Rie, A., 2004). In the 1940s the whole 
cell pertussis vaccine consisted of inactivated suspensions of the whole Bordetella 
pertussis bacteria (WHO, 2013). The pertussis vaccine was approved for routine use by the 
American Academy of Pediatrics in 1943, and in 1944 the American Medical Association 
recommended its use. (CDC, 2013; Shapiro–Shapin, 2010). Halperin, S.A. (2007) describes 
the benefits of the whole cell pertussis vaccine provision to communities in the 1940s and 
its effectiveness in reducing pertussis rates to its lowest in the U.S. until the 1980’s (p.111). 
Statistics from the Centers of Disease Control describe the effect of vaccines on disease 
incidence by stating: “In 1934 the whooping cough incidence in the U.S. was 209 
cases/100,000 residents, and the death rate was 5.9/100,000, yet by 1948, routine use of 
the vaccine reduced the incidence to 51 cases/100,ppp and death rate to <1/100,000. After 
1960 incidence was 10 cases/100,000” (2013).  
 In regards to the use of whole cell pertussis vaccine outside the U.S., the World 
Health Organizations (WHO) indicates, “whole cell pertussis vaccine were first 
formulated in 1963 and revised and incorporated into recommendations for DTP in 
1978. In 1989 the recommendations for the combined vaccine were revised and 
most recent revised recommendations for whole cell pertussis vaccines were 
adopted by the ECBS in 2005” (WHO, 2013).  
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1.7 Acellular Pertussis Vaccine (aP) 
 In efforts to limit negative vaccine side effects of the whole cell pertussis vaccine, 
acellular pertussis vaccines were introduced in 1991 as booster shots and as 
immunizations for primary vaccination in 1997 (Zhang, 2008). Acelluar vaccines were 
made up of components of purified, detoxified B. pertussis antigens (WHO, 2014). Use of 
these acellular vaccines versus whole cell vaccines helped to protect individuals from 
disease while decreasing side effects of redness and swelling that were often associated 
with whole cell pertussis vaccine administration (Zhang, 2008). Pertussis vaccinations 
were administered in a series of shots to maintain immunity.  The number of doses 
recommended varied by country though most schedules included at least 3 doses of 
pertussis vaccine to be given before six months of age in infants (Tan, Trindade & 
Skowronski, 2005).  In the U.S., a complete pertussis immunization schedule for children 
included a series of five immunizations, with the final dose given between 4-5 years old 
(CDC, 2013). However, with the reemergence of pertussis in highly immunized populations, 
an adolescent booster dose of the acellular pertussis vaccine became available and also 
recommended. In May 2005, the FDA approved Tdap, a tetanus and diphtheria booster 
immunization that also included an acellular pertussis booster component. The Tdap 
immunization was first approved as a booster dose for ages 10-18 years in May 2005 and 
then as the first pertussis booster vaccine in adults ages 11-64 years in June 2005 
(Dworkin, M.S., 2005). Whole cell vaccines were completely stopped from use in the U.S. in 
2001 (Witt, M.A., Arias,L., Katz, P.H., Truong, E.T., & Witt, D.J., 2013), although it is still 
commonly used in developing countries due to the decreased cost of vaccine (WHO, 2014).                                                                                                                   
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1.8 Burden of Disease                                                                                                                              
 The burden of pertussis disease has shown significant impact on both developing 
and developed nations. Estimates by the World Health Organization (WHO) state that in 
2008, “16 million cases of pertussis occurred worldwide, 95% of which were in developing 
countries, and that about 195, 000 children died from the disease” (2011). Another 
source’s findings describe global pertussis rates as attributing to 50 million cases and 
300,000 deaths every year (He, 2008).  Many of these developing nations are under-
immunized for pertussis due to low socioeconomic conditions such as poverty and lack of 
quality healthcare structures. The Global Vaccine Action Plan (GVAP) started by the World 
Health Organization aims to increase vaccination rates in countries with low immunization 
coverage. According to the World Health Organization, the GVAP was developed to provide 
a framework of goals for prevention of vaccine preventable diseases globally (2014). The 
GVAP 2011-2020 defines a vaccine goal that “by 2020, coverage of target populations 
should reach at least 90% national vaccination coverage and at least 80% vaccination 
coverage in every district or equivalent administrative unit for all vaccines in national 
immunization programmes” (WHO, 2014).  A study by Jackson and Rohani (2012), which 
assessed the global burden of pertussis disease in the last twenty years, concluded that 
developing countries continue to have high mortality and morbidity rates due to pertussis 
while specific developed countries with high immunization rates continue to experience 
resurgence in whooping cough (p. 2). Though Jackson and Rohani’s results showed that a 
“mix of increasing, stationary, and decreasing trends in high-coverage countries” (p. 2) and 
a “lack of consistent geographical pattern in the trends” (p.3), increased incidence rates 
were reported in the 1980s for high vaccine coverage countries such as the U.S., Israel, 
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Australia, and Poland (p. 2).  Challenges in regards to comparing rates of pertussis among 
highly immunized nations involve differences in vaccine schedules and variations in 
vaccine and disease tracking. Clark, T. A., Messonnier, N.E., & Hadler, S.C. (2012) states, 
“Differences in vaccination programs and surveillance systems limit the direct comparison 
of pertussis burden among countries” (p. 211). Researchers also attribute challenges due to 
variations in immunization coverage which impacts how the epidemiology of pertussis in 
the nation is interpreted (Wood, N & McIntyre, (2008), p.202). In the U.S., the CDC reported 
48,277 cases in 2011, with increased disease incidence seen among 7- 10 year olds in 2010 
and among 13-14 year olds in 2012 (2014).  Many more pertussis cases in highly 
immunized populations may be undiagnosed. Infants continue to remain the most 
vulnerable population being affected by pertussis reemergence, as hospitalization and 
death often occur in this age group due to challenges in recovery (CDC, 2014). 
 
1.9 Epidemiological Shift  
 A resurgence of pertussis disease began to emerge in highly immunized countries, 
such as in the U.S. in 1982 with peaks in 2005, 2010, and 2012 (Cherry, 2012). Halperin 
(2007) discusses the epidemiological shift seen in many highly immunized countries from 
increased cases seen in infants and children to adolescents and adults (p. 111). Leung, 
A.K.C. & Robson, W.L.M. (2007) describes this shift stating,  “in recent years, almost 50% of 
reported cases occurred in individuals older than 10 y of age; the greatest increase has 
been noted in individuals 10 to 19 y of age” (Leung, A.K.C. & Robson, W. L.M., (2007), p. 
355). Though pertussis in many adolescents and adults may present as mild illnesses and 
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even go unnoticed, the exposure of infants to these infected individuals may result in 
pertussis transmission in which severe illness and death can occur (Leung, A.K.C. et al. 
(2007) p. 354). Abuhammour (2008) further relates the increased infection rates of infants 
to possible exposure through contact with adolescents and adults. Dworkin, M.S. (2005) 
stresses the importance of identifying cases of pertussis in adolescents and adults to help 
stop the cycle of transmission to infants (p. 44). 
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METHODS 
 2.1 Literature Search Strategy 
 A literature search on January 17, 2014, was conducted using PUBMED AND EBSCO 
databases with key word phrase searches including the terms “pertussis and reemergence”, 
pertussis and recurrence”, “pertussis and comeback”, “pertussis and resurgence, 
“whooping cough and re-emergence”, “whooping cough and recurrence”, “whopping cough 
and comeback” and “whooping cough and resurgence”.  Restrictions were placed on journal 
articles published within the last ten years and to research written in English.  A second 
search was conducted on March 11, 2014 using the same key word phrases to verify 
inclusion of all pertaining articles. All primary articles that included data on risk factors 
associated with the resurgence of pertussis from 2004-2014 were included in this review.  
 
2.2 Primary Outcome  
 All primary studies that assessed risk factors in association with pertussis infection 
as the primary outcome between 2004-2014 were included in this systematic review. 
 
2.3 Inclusion Criteria 
▪ Studies from countries with greater than or equal to 90% infant vaccine coverage 
for the third dose of pertussis vaccine specific to the year(s) in which the study was 
conducted 
▪ Primary articles looking specifically at risk factor association and using data from 
human studies 
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▪  Studies published within the years 2004-2014 in which all data or part of the data 
was collected between 2004-2014 
 
 2.4 Exclusion Criteria (see Figure 1 and Table 1) 
▪ Studies in which pertussis was not the main focus of the article 
▪ Research printed in a language other than English 
▪ Studies that were not primary studies identifying risk factor association to pertussis 
infection (includes review articles, descriptive articles, surveillance articles, case 
reports, intervention studies)  
▪ Research conducted in countries exhibiting low immunization coverage, less than 
90% of infant vaccine coverage for three doses or pertussis vaccine between 2004-
2014 
▪ Studies involving animal models or mathematical models 
▪ Research containing data retrieved before 2004 
 
2.5 Data Collection  
 Articles were organized into tables (see Tables 2-4), defining highly immunized 
countries where each study took place, study design, the researchers’ end point being 
pursued from the article, risk factor identified, and results of the article. After identifying a 
list of articles from the initial search with use of various keywords, abstracts were 
reviewed and exclusion of articles that were non-English and articles in which pertussis 
was not the main focus were excluded from the review. Data analysis continued as full 
articles were reviewed and exclusion of non-primary study articles regarding pertussis was 
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initiated. Animal models, mathematical models, and studies with data from countries of low 
immunization coverage or with data collected prior to 2004 were also excluded from the 
review. A final list of fourteen primary studies were reviewed and then grouped together 
based on category of risk factor identified by the authors. The two largest categories of risk 
factors in which common article themes were found included the risk factor of waning 
immunity and bacterial changes. Four articles were grouped in the waning immunity list, 
while six articles were grouped in the bacterial changes list. A third category of articles was 
created based on one unifying article that included each of the following risk factors: non-
medical exemptions, inadequate childhood immunization, inadequate provider awareness, 
and household transmission.  
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Figure 1:  Flow Diagram of Literature Search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 Articles 
initial search 
 PubMed 
 and EBSCO 
109 Articles 
 PubMed and EBSCO 
  
43 Articles 
PubMed and EBSCO 
  
14 Articles 
included in final review 
PubMed and EBSCO 
  
39 Articles  
(Pertussis not main 
focus, Non-English 
articles) 
68 Articles  
(Group meetings, 
review, descriptive, 
surveillance, and non-
primary study articles) 
29 Articles 
(Intervention studies, 
Non-human models, low 
immunization country, 
case reports, data 
outdated) 
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Table 1: Excluded Articles  
 
Reason for Exclusion Number of 
Articles 
Non-primary study articles 
(review articles and descriptive articles defining pertussis, diagnosis, 
lab reporting, symptoms) 
43 
Topic (articles where pertussis is not main topic) 22 
Non-English 17 
Vaccine (history, description, developments, side effects) 15 
Intervention articles 12 
Surveillance 8 
Countries with low immunization coverage 7 
Immunity (not primary studies) 7 
Animal models 6 
Mathematical models 3 
Case reports 3 
Group meetings regarding pertussis 3 
Data outdated (collected prior to 2004) 2 
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Table 2: Waning Immunity 
Author/
Year 
Country  Type of 
Study 
Endpoint  Risk Factor 
Identified 
Results 
Witt, M.A., 
Arias, L., Katz, 
P.H., Truong, 
E.T. & Witt, 
D.J. 
 (2013)  
U.S. Observational 
Study  
Immunity Use of acellular 
vaccines 
Use of a complete 
acellular vaccine 
series is less 
effective than one or 
more doses of whole 
cell pertussis 
vaccine (RR= 8.57) 
Smits et al. 
 (2014)  
Belgium  Observational 
Study 
  
Immunity Use of acellular 
vaccines 
Use of wP induces 
longer lasting 
immunity than aP 
Trollfors, B., 
Dotevall, L., 
Sundh, V 
&Welinder-
Olsson, C. 
 (2011)  
Sweden Observational 
Study 
  
Immunity  Use of infant 
vaccine series 
only without 
more booster 
doses 
Booster pertussis 
doses needed, 
number of booster 
doses and timing of 
doses for effective 
immunity still 
unknown 
Han, W.G.H.  
et al. 
 (2013)  
Netherlands  Observational 
Study  
Immunity  Limited 
immunological 
memory 
Long-term 
immunity after 
infection is often 
lost in older age 
groups  
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Table 3: Bacterial Changes 
 
 
Author/
Year 
Country  Type of 
Study 
Endpoint  Risk Factor 
Identified 
Results 
Pawloski, L.C. et 
al. (2014) 
U.S.  Observational 
Study 
(Screening of 
13000 isolates 
from outbreak 
and surveillance 
studies) 
Bacterial mutations Pertactin-deficient B. 
Pertussis Strains 
Recent dramatic increase 
in pertactin-deficient B. 
pertussis isolates 
throughout the U.S. 
Gent, M.V., 
Bart,,M.J, Han, G.J., 
Hedie, V.D., 
Heuvelman, K.J., & 
Mooi FR.R., (2012) 
Netherlands Observational 
Study 
  
  
  
  
Bacterial mutations Pathogen 
Mutations/Adaptation 
Small mutations can drive 
large changes of bacterial 
pathogen and may cause 
resistance to vaccination 
Kallonen,T. et al. 
(2011) 
Finland  
Poland 
Serbia  
UK 
Observational 
Study 
Bacterial mutations Bacterial mutations Possible vaccine-driven 
differences in genomic 
content between old and 
recent  vaccine strains 
among 4 different 
countries 
King, A.J. et al. 
 (2008) 
Netherlands Observational 
Study 
Bacterial mutations Bacterial  mutations Emergence of ptxP3 
strains through bacterial 
adaptation causing 
divergence between 
vaccine and circulating 
strains. 
Shuel, M. et al. 
(2013) 
Canada Observational  
Study 
  
  
 Bacterial  strain 
domininace 
Dominance of 
pertussis strain 
One predominant B. 
pertussis clone in Ontario, 
Canada identical to strains 
involved in epidemics in 
Europe and Australia 
Abu Raya B et al. 
(2012) 
Israel 
  
Observational 
Study 
(2 years) 
Bacterial strain 
dominance 
Predominance of 
strains 
Circulating strains in Israel 
during high incidence rate 
years are similar to strains 
found in Europe  
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Table 4:  Inadequate Immunization Coverage/ Provider Awareness 
 
 
 
Author/Year Country  Type of 
Study 
Endpoint  Risk 
Factor 
Identified 
Results 
Atwell, J.E.(2013) U.S. Observational 
Study 
Infection Route Non-Medical 
Exemptions 
(NMEs) 
NMEs: source of  
pertussis outbreak in 
California 2010 
CDC, MMWR 
(2013) 
U.S. Survey Immunization 
coverage 
Inadequate 
Childhood 
immunization 
Low SES and poverty 
may be contributing 
factors to inadequate 
childhood immunization 
dispersed across the U.S. 
Kwon, H.J., Yum, 
S.K., Choi, U.Y., Lee, 
S.Y., Kim,J.H, 
&Kang,J.H.(2012) 
South Korea Observational 
Study 
  
Infection 
Route/ 
Immunization 
Coverage 
Household 
Transmission 
Household 
transmission/ 
inadequate infant 
immunization 
Abuhammour, W. 
(2007) 
U.S. Survey Diagnosis Inadequate 
provider 
knowledge 
Misdiagnosis of pertussis 
patients leads to 
ineffective infection 
detection and control 
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RESULTS 
 
3.1 Waning Immunity  
 
 In this review, four studies were identified that focused on waning immunity as a 
risk factor associated with pertussis re-emergence. Witt, M.A., Arias, L., Katz, P.H., Truong, 
E.T. & Witt, D.J.(2013) looked at the association of pertussis incidence with the type of 
pertussis vaccination received, assessing whether receiving whole cell pertussis (wP) 
vaccine at any point showed a lower risk of pertussis infection versus those who had 
received only acellular pertussis (aP) vaccines. Access to Kaiser Permanente’s (KP) 
electronic medical records allowed researchers to examine lab confirmed pertussis results 
and vaccine histories for 263,496 patients ages 8-20 years old born between 1990-2001. 
904 cases of pertussis were found among these patients. Results showed an increased risk 
of pertussis cases being highest in those who received 5 doses only of aP vaccine for both 
groups (RR= 8.75, P<.0001) when compared to patient histories who received at least one 
dose of wP. Members who received all 6 doses of aP had a 3.55 relative risk of pertussis (P< 
.0001) when compared to those with at least one dose of wP. Though a decreased risk of 
pertussis was seen in patients who received 6 doses versus five doses of only aP vaccine, 
this group still exhibited a high relative risk for pertussis infection when compared to those 
who had one or more doses of wP vaccine. The authors concluded that use of only acellular 
vaccines in a vaccination series of 5 doses provides a shorter immunity span than when 
one or more immunizations of whole cell vaccines are included in an immunization series.  
The authors also concluded that patients who received a sixth booster dose of acellular 
vaccine in a series of aP vaccine exhibited a longer lasting immunity against pertussis.   
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Smits et al (2014) assessed a cohort of 24 Belgian preadolescents with a median age 
of 10.1 years old.  Through collected blood samples, indications of residual T cell memory 
were evaluated.  Participants included those who received a pertussis vaccine from infancy 
through the last pertussis booster shot. The last booster shot was given at a median 
interval of 4.8 years for wP vaccinated children and at a median interval of 2.7 years for aP 
vaccinated children (p=0.004) from the last pertussis vaccine. Eleven adolescents had 
received wP in infancy and 13 adolescents had received aP in infancy. All 24 participants 
received aP as their last pertussis booster dose. Results showed that individuals who 
received the wP pertussis immunization in infancy had longer lasting immunity than those 
individuals who were vaccinated with aP as infants.  
 The study by  Trollfors, B., Dotevall, L., Sundh, V &Welinder-Olsson, C. (2011) 
involved outcome assessment of a mass vaccination project in Gothenburg, Sweden held 
between 1995-1999 from infants to 10 years of age. Pertussis incidence was assessed 
between 1999-2009 through PCR and culture verified lab cases and hospitalizations. 
Among 1,973 cases identified, 450 cases were from patients who had received 3 doses of a 
monocomponent pertussis vaccine with highest incidence seen in infants below the age of 
12 months of age. A recurrence of pertussis infection was seen in 1999 with a peak in 2004, 
marking an outbreak of the disease. However, disease incidence decreased again after 2004 
when booster doses began to be recommended for children 10 years of age from 2005-
2006 and for children 5-6 years of age from 2007 onwards. Study outcomes revealed a 
shorter span of immunity in pertussis vaccinations with improvement in immunity 
occurring when booster doses were given.  
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Finally, a study by Han et al (2013) conducted in the Netherlands analyzed blood 
samples for 62 pertussis patients at various time periods after infection.  The age range was 
between 9.4-78.9 years with a median age of 37.5 years. Samples were placed in groups of 
< 30 years old, > or equal to 30 years old,  < 3 months after diagnosis, and > or equal to 3 
months after diagnosis. The blood sample analysis involved B. pertussis-specific (memory) 
CD4+ T cell activity at the epitope-level at different time periods after pertussis diagnosis. 
The authors state, “ long-lived Th1 CD4+T cells are essential for protective immunity 
against pertussis.” (p.1). Results showed a decrease in these memory cells among the older 
age group of this study who were previously infected. One conclusion by the researchers 
state, “Loss of multi-epitope specificity in memory pertussis CD4+ T cell responses could 
play a role in waning effectiveness of pertussis immunity in older age groups. These 
observations can have implications for vaccination strategies and vaccine development” (p. 
5). The authors concluded a loss of long- term immunity occurs after infection in older age 
groups and recommended use of this knowledge of “limited immunological memory to B. 
pertussis” in future research towards novel vaccine development (p. 1, 5). 
 
3.2 Pertussis Bacterial Strain Changes 
  
 Six studies in this systematic review involved analysis of pertussis bacteria strains 
to determine changes in the structure of the bacteria over time, while discussing the 
association of pertussis resurgence to mutation and adaptation of bacterial strains causing 
resistance against vaccines.   An Australian study by King et al. (2008) identified pertussis 
bacterial strains with genetic changes in which the absence of 98 genes were found in “at 
least one of the b. pertussis strains tested” among 43 Dutch isolates between 1993-2004 
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(p.1).  The authors discuss emergence of ptxP3 strains through bacterial adaptation causing 
“divergence between vaccine and circulating strains” and pertussis resurgence.  
In another study by Kallonen et al. (2011), researchers examined old pertussis 
isolates (1941-1984) and more recent isolates (1996-2004) from Finland, Poland, Serbia, 
and the UK and identified genomic differences among the pertussis strains compared 
(p.2041, 2011). Since the reference bacterial strain Tohama I was used for production of 
both whole cell and acellular pertussis vaccines, strain resistance to pertussis vaccinations 
is highlighted due to changes in the bacterial genetic material over time (p. 2041).  
In the study conducted by Pawloski et al. (2014), researchers looked at 1,300 
pertussis isolates dated from 1935- 2009 in the U.S. and identified 306 isolates lacking 
pertactin (p. 119). These results show a link to the possible ineffectiveness of the acellular 
vaccine since pertactin is a significant antigen component in the acellular pertussis vaccine.  
The study conducted by Gent, M.V., Bart, M.J, Han, G.J., Hedie, V.D., Heuvelman, K.J., & 
Mooi FR.R., (2012) assessed 704 Dutch pertussis strains between 1949-2010 also showed 
genetic mutations in pertussis bacteria. The authors concluded that even small genetic 
changes over time can produce unique pertussis bacterial strains. Increases in pertussis 
outbreaks could thus be attributed to unique pertussis bacterial strains emerging in 
resistance to vaccines.  
In support of this notion, two studies identified similarity of strains found during 
outbreak seasons to that in other highly immunized countries. A Canadian study in 2013 
examining 521 pertussis isolates from 1998-2006 showed similarities to pertussis isolates 
during epidemics in Europe and Australia, suggesting one predominant clone of pertussis 
bacteria having emerged and is related to the pertussis resurgence (Shuel et al. 2013). 
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Research conducted on pertussis strains in Israel between 2007-2008 identified a 
predominance of specific pertussis strains correlating to the most common European 
pertussis strain between 1999-2004 (Abu Raya B et al. 2012).  These similarities in 
outbreak strains may signify an emergence of dominant pertussis strains correlating with 
pertussis mutations which differ from vaccine strains, thus leading to “increased pertussis 
activity” (p.762). 
 
3.3 Non-Medical Exemptions 
 Lower rates of childhood immunization, either through higher frequency of non-
medical exemptions or lower socioeconomic levels, were also identified as a risk factor for 
the resurgence of pertussis.  A California study initiated after a major pertussis outbreak in 
2010 identified unimmunized children through non-medical exemptions (NME’s) as being 
a primary route of transmission of pertussis in highly immunized communities (Atwell, 
2010). Researchers concluded pertussis re-emergence stemmed from clusters of non-
medically exempted children experiencing pertussis infection and spreading it to other 
individuals within the higher immunized communities. 
 
3.4 Inadequate Child Pertussis Immunization Rates 
 The National Immunization Survey (NIS), initiated through the CDC, conducted a 
random–digit-dialed telephone survey among households in the U.S. for children aged 19-
35 months (CDC, 2013). Results for children born during Jan 2009- May 2011 showed 
 82.3% pertussis immunization coverage for greater than or equal to 4 doses of Dtap  
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which was actually below the Healthy People 2020 target percentage of 90% (p.733).  
Other specific results from this study included inconsistencies of immunization rates across 
the U.S. states and decreased pertussis immunization rates in families under poverty level 
(CDC,2013). Researchers defined the significant risk of low immunization coverage as 
“clusters of unvaccinated children leave communities vulnerable to outbreaks of disease” 
(p. 739). This study revealed low immunization coverage in children across the U.S., often 
correlating with low socioeconomic status, while exposing a possible route of pertussis 
infection among children in the U.S. 
 
3.5 Inadequate Provider Knowledge 
 One study identified inadequate provider knowledge of pertussis identification and 
recurrence as a risk factor to the re-emergence of pertussis. Results of a 2007 health care 
provider survey distributed to physicians in Michigan showed a “decreased awareness” of 
the current need in identifying and diagnosing pertussis in adolescent and adult 
populations (Abuhammour, 2008). The survey included a case study to be reviewed by 
physicians with pertaining questions that followed. Results indicated a decreased 
identification of pertussis as a “differential diagnosis of adults with respiratory tract 
illness” (p. 44).  Inadequate provider awareness of the importance in considering pertussis 
as a differential diagnosis in patients could lead to misdiagnosis and decreased 
identification and treatment of patients with pertussis, leading to increased risk of 
exposure to individuals in close contact with these infected persons. 
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3.6 Household Transmission 
 A prospective multicenter study conducted in South Korea recognized household 
transmission of pertussis among family members as the main route of transmission for 
infants below the age of six months (Kwon, H.J., Yum, S.K., Choi, U.Y., Lee, S.Y., Kim, J.H. & 
Kang, J.H., (2012) p.2). The authors indicate 85.7% of infant transmission was associated 
with contact from an infected parent though they did not specify the immunization status 
of the parent. In this cohort, all but one of the twenty-one infants showed an incomplete 
pertussis vaccination history. As infants less than the age of one are at highest risk for 
experiencing symptoms of pertussis that may lead to morbidity and/or mortality, this 
study shows the significance of ensuring infants receive the complete pertussis vaccination 
series and that parents and caretakers are up to date on booster pertussis vaccinations as 
being essential to decreasing infant pertussis transmission. 
 
 
DISCUSSION 
 Public health efforts towards reducing pertussis transmission in communities with 
high immunization rates lie not only in keeping vaccination rates high, but also in 
addressing risk factors that are unique to pertussis transmission in highly vaccinated 
populations. Waning immunity through decreased efficacy of acellular vaccines and vaccine 
ineffectiveness due to genetic changes in pertussis bacteria are two main points addressed 
in this review.  The promotion of immunization and educational interventions along with 
future research toward new vaccine development is essential in addressing the resurgence 
of pertussis in highly immunized populations. 
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4.1 Waning Effectiveness of Immunizations 
 Two studies point towards the recent use of the acellular vaccines versus whole cell 
vaccines as a contributor to pertussis comeback due to decreased long-term effectiveness 
of immunization series that contain only acellular vaccines (Smits et al. 2014; Witt et al. 
2013).  A study in Belgium evaluated T cell responses in preadolescents who had been 
vaccinated and identified longer lasting immunity in those with whole cell vaccinations 
(Smits et al. 2014). After a thorough evaluation of electronic medical records, Witt et al. 
(2013) correlated an increase in pertussis cases among individuals with acellular 
vaccination versus those who received at least one dose of whole-cell pertussis vaccine in 
the U.S. state of California. Both studies discussed the long-term effectiveness seen in whole 
cell pertussis immunization series versus acellular pertussis immunization series. These 
studies point to the idea that the shift to acellular vaccines from whole cell vaccines may be 
a driving factor contributing to the pertussis reemergence. Since acellular vaccines began 
replacing whole cell vaccines as booster shots in 1991, as primary immunizations in 1997, 
and completely in 2001, one hypothesis posited through these studies is that the use of 
acellular vaccines may contribute to the waning immunity observed in countries such as 
the U.S. and underlie the pertussis outbreaks among highly immunized communities. 
 
4.2 Bacterial Changes Leading to Vaccine Ineffectiveness 
 Bacterial mutations and specific genomic variations of new pertussis strains may 
affect vaccine effectiveness as current pertussis vaccines were once developed to target 
older pertussis bacterial strains. Of the six articles identifying changes in bacterial strains 
of pertussis as being associated with whooping cough re-emergence, four articles discussed 
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genetic mutations and differences in new pertussis bacteria strains (Gent, M.V., 2012; King 
et al., 2008; Pawloski, L.C. et al. 2014; King et al. 2008). Pawoloski’s study identifying 
pertactin deficient pertussis bacteria provides insight into the ineffectiveness of long-term 
immunity with acellular vaccines due to bacterial mutation, as pertactin is an important 
component of the acellular pertussis vaccine (2014). A study by van Gent, M.V (2012) 
concluded that small genetic mutations within a time span of 6 to 19 years may cause 
resistance to vaccination, confirming the idea of bacterial mutations affecting efficacy of 
current vaccines. The study from Australia by King et al. (2008) also describes bacterial 
adaptation and pertussis emergence that can recur through divergence between changed 
circulating bacterial strains and vaccines. The study consisting of data from Finland, 
Poland, Serbia, and the UK describe these bacteria changes noting clear differences in the 
structure of old circulating pertussis bacteria versus newer strains (Kallonen et al. 2011). 
Two studies in Canada and Israel each point towards a dominant pertussis strain having 
emerged and showing identity to pertussis bacterial strains from outbreaks across Europe 
(Shuel, M. et al. (2013); Abu Raya B et al. 2012). These results tie into the theory of new 
pertussis strains with increased fitness emerging across the world, thus causing decreased 
vaccine effectiveness of currently available pertussis vaccines. 
 
4.3 Immunization Interventions 
 Promotion of immunization programs to all age groups as a prevention intervention 
can greatly help control pertussis outbreaks. Until a novel vaccine is approved for 
distribution, pertussis vaccination among children, adolescents, and adults is an important 
aspect to pertussis prevention. The importance of initiating quality immunization 
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intervention strategies to children, adolescents, and adults is to help ensure completion of 
childhood pertussis immunization series while preventing the transmission of pertussis 
from adolescents and adults to infants. The National Immunization Survey (NIS), initiated 
through the CDC, concluded that vaccination rates vary across states in the U.S. and groups 
of unvaccinated children often live under poverty level (2011). These unvaccinated 
children could be the source of transmission of whooping cough. Continued promotion of 
immunization programs in underserved areas may help decrease rates of unvaccinated 
children while helping maintain comparable rates of immunization across the U.S. and 
other highly immunized countries. 
 As the current epidemiological shift of pertussis rates show a larger percentage of 
confirmed pertussis cases in adolescents and adults, vaccination efforts to confirm and 
promote booster pertussis immunizations in adolescents and adults can help decrease 
disease transmission to infants. A study by Trollfors, B., Dotevall, L., Sundh, V & Welinder-
Olsson, C.(2011) stresses the need for booster doses in children and adolescents as the 
study revealed how pertussis incidence can reoccur in children who only received infant 
pertussis doses versus those who received a booster vaccine in adolescence. The study by 
Han et al. (2013) showed how booster doses for adults is a significant component of 
pertussis prevention due to decreased T cell memory responses in older age groups who 
had previously been infected with pertussis. Immunization programs, focusing on 
immunizing parents and household members can also help with pertussis prevention. The 
study by Kwon, H.J. et al. (2012) revealed a large percentage of infant pertussis 
transmission occurring through household contacts may benefit from cocooning 
immunization intervention strategies. Cocooning is a method of immunizing healthcare 
 38
providers and family members who come in constant contact with newborns. Cherry 
(2012) encourages cocooning, immunizing pregnant women and promoting earlier 
immunization series for infants as a way of helping to decrease pertussis transmission in 
infants (p. 787).  
 
4.4 Patient Education 
 One article in this review discussed unvaccinated children being a risk factor 
associated with the resurgence of pertussis and recent outbreaks in the U.S. Researchers 
associated the clusters of non-medical exempted children from attaining pertussis 
vaccinations with the 2010 outbreak of pertussis in California (Atwell, 2010). This 
outbreak resulted in >9000 cases, 809 hospitalizations, and 10 infant deaths. (Winter et al. 
2012). Educating parents on the need of initiating and completing the pertussis 
immunization series in children and the benefits versus risks/side effects of vaccination 
can help decrease transmission of the disease from those who are not fully immunized to 
the communities in which they reside. 
 
4.5 Provider Education 
 Educating health care providers on the importance of recognizing pertussis as a 
diagnosis for respiratory symptoms in adolescents and adults will also help decrease 
transmission of the disease through early recognition and treatment of disease. The survey 
results from family physicians in one northern state in the U.S. emphasized the need to 
increase physician awareness of pertussis being a differential diagnosis in patients with 
cold symptoms and/or prolonged cough (Abuhammour, 2008).  Increased accurate 
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identification of pertussis cases by health care providers can help decrease transmission of 
pertussis by treating patients and their contacts accordingly. Interventions that accentuate 
the role of health care providers in preventing the spread of pertussis through promotion 
of vaccination and patient education may significantly impact public health efforts toward 
pertussis prevention (Abuhammour, 2008). 
 
4.6 Collaboration Across Multiple Disciplines 
 Ten of fourteen studies in this review including data from eleven countries and 
three continents, point towards either waning immunity and/or bacterial changes as risk 
factors associated with pertussis resurgence. The two risk factors of waning immunity and 
bacterial changes may therefore be related in that mutations and adaptations of pertussis 
bacteria over time may be linked to the inability of current vaccines to address the correct 
pertussis antigen, leading to ineffectiveness of vaccine induced long-term immunity.  
 Collaboration of multiple disciplines is an important step to addressing pertussis 
prevention efforts in highly immunized communities. Clark, T.A., Messonier, N.E, Hadler, 
S.C. (2012) states, “It is time for all disciplines of vaccinology- epidemiology, microbiology, 
and immunology- to take up challenge of understanding this problem and try to solve it” (p. 
21). Continued research efforts into understanding the combined areas of epidemiology of 
pertussis reemergence, the biological make-up of current pertussis strains, effectiveness of 
vaccines and immunology, and its’ relation to current outbreaks in countries with high 
immunization coverage should be encouraged and increased. 
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4.7 New Vaccine Development 
 In efforts to address both the waning immunity of acellular vaccines and emergence 
of mutated pertussis bacteria with increased fitness, development of a new pertussis 
vaccine should be a significant focus in public health. Clark, T. A., Messonnier, N. E., & 
Hadler, S. C. (2012) discuss the importance of pertussis control through development of a 
new vaccine and emphasize the focus of this development as “durable immunity and the 
ability to interrupt transmission, not just to protect against severe or symptomatic disease” 
(p.212).  
 
4.8 Strengths 
 Strengths of this systematic review include the use of a variety of terms to retrieve 
the most expansive list of articles published regarding risk factors associated with 
pertussis resurgence. Evaluating published articles in the last ten years allowed for the 
most recent and updated studies to be reviewed. Research results and conclusions 
obtained between 2004-2014 allowed for a targeting of recent outbreaks, updated data, 
and current risk factors focusing on immediate public health interventions and efforts 
towards future research strategies. Articles included in this review included studies from 
several highly immunized countries in various continents, showing similarities of results in 
different regions of the world, especially in regards to bacterial mutations.  
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4.9 Limitations   
 There are various limitations in this systematic review including having only 
published articles from PUBMED and EBSCHO included in this review and not grey 
literature or other databases.  Searches based only in English may have limited data and 
associations than those found in studies published in other languages. Limitations may 
have occurred in the time frame in which the reviewer conducted the search for this 
review.  Differing immunization schedules and timing of when the aP vaccine was solely 
administered to children and as booster doses, may affect comparison between waning 
immunity studies between various highly immunized countries. 
 
4.10 Bias 
 Bias may have occurred in results found in published articles versus research found 
in articles that were not published.  Possibility of reviewer bias may have occurred in 
regards to the shortened time frame of the literature search and article retrieval and 
assessment. 
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4.11 Conclusion 
 
● Waning immunity through replacement of whole cell vaccines with acellular vaccines 
may be a driving risk factor towards pertussis resurgence 
● Bacterial mutations and increased dominance of specific pertussis strains with 
increased fitness may be associated with vaccine ineffectiveness leading to pertussis 
reemergence 
● Inadequate immunization coverage through non-medical exemptions, inadequate 
completion of childhood immunization series, and inadequate adult booster dose 
immunization coverage may cause increases in pertussis recurrence  
● Inadequate provider awareness leading to misdiagnosis and delayed treatment of 
infected patients and contacts may contribute to pertussis resurgence 
● Promotion of immunization and educational interventions to infants, children, 
adolescents, and adults is an important aspect to pertussis transmission control 
● Educating healthcare providers on the importance of recognizing pertussis as a 
differential diagnosis for patients with symptoms of prolonged cough is a key 
component to decreasing the spread of pertussis 
● Future research involving collaboration across multiple disciplines is essential to 
understanding the risk factors associated with and addressing the resurgence of 
pertussis in highly immunized populations 
● Future research into novel vaccine development is a significant aspect to protecting 
populations from newly emerging dominant pertussis strains 
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